U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H26N6O2
Molecular Weight 394.4701
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUISINOSTAT

SMILES

CN1C=C(CNCC2CCN(CC2)C3=NC=C(C=N3)C(=O)NO)C4=C1C=CC=C4

InChI

InChIKey=PAWIYAYFNXQGAP-UHFFFAOYSA-N
InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)

HIDE SMILES / InChI

Molecular Formula C21H26N6O2
Molecular Weight 394.4701
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Quisinostat is an orally bioavailable potent histone deacetylase inhibitor, specifically selected due to its sustained inhibition of HDAC1 in solid tumor tissues and prolonged period of half-elimination from tissues. Phase 2 clinical trials are ongoing in patients with platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Quisinostat is active in the treatment of patients with relapsed or refractory Sézary syndrome. The most common drug-related adverse events reported in this trial were: nausea, diarrhea, asthenia. Grade 3 adverse events were also reported: hypertension, lethargy and pruritus.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.11 nM [IC50]
0.33 nM [IC50]
0.37 nM [IC50]
0.46 nM [IC50]
0.64 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
2010 Feb
Patents

Sample Use Guides

12 mg capsule on days 1, 3, and 5 of each week in a 21-day treatment cycle
Route of Administration: Oral
Quisinostat inhibited cell proliferation in all lung, breast, colon, prostate, brain, and ovarian tumor cell lines tested, with IC50 values ranging from 3.1 to 246 nM/L.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:40:28 GMT 2023
Edited
by admin
on Sat Dec 16 01:40:28 GMT 2023
Record UNII
9BJ85K1J8S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUISINOSTAT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
JNJ-26481585
Code English
Quisinostat [WHO-DD]
Common Name English
N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)piperidin-1-yl]pyrimidine-5-carboxamide
Systematic Name English
quisinostat [INN]
Common Name English
QUISINOSTAT [USAN]
Common Name English
5-PYRIMIDINECARBOXAMIDE, N-HYDROXY-2-(4-((((1-METHYL-1H-INDOL-3-YL)METHYL)AMINO)METHYL)-1-PIPERIDINYL)-
Systematic Name English
JNJ 26481585
Code English
Classification Tree Code System Code
NCI_THESAURUS C1946
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C77912
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
FDA UNII
9BJ85K1J8S
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105763
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
WIKIPEDIA
Quisinostat
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
INN
9452
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID90236376
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
DRUG BANK
DB12985
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
SMS_ID
100000166929
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
CAS
875320-29-9
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
EVMPD
SUB181224
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
PUBCHEM
11538455
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
USAN
XX-125
Created by admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
It is approximately 500-fold more potent than vorinostat at inhibiting HDAC1.
IC50
TARGET->WEAK INHIBITOR
IC50
TARGET->WEAK INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET ORGANISM->INHIBITOR
TARGET->WEAK INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY